Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

AUTOIMMUNE DISEASE

Circulating TFH cells as a marker for early therapeutic intervention in T1D

Costimulatory blockade via the CTLA-4–Ig fusion protein abatacept is beneficial in patients with early-onset type 1 diabetes, but some individuals benefit more than others. A new study reports that the pretreatment abundance of T follicular helper (TFH) cells could predict clinical responses to abatacept.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Model for the mechanism of action of abatacept in T1D.

References

  1. Orban, T. et al. Lancet 378, 412–419 (2011).

    Article  CAS  Google Scholar 

  2. Orban, T. et al. Diabetes Care 37, 1069–1075 (2014).

    Article  CAS  Google Scholar 

  3. Edner, N. M. et al. Nat. Immunol. https://doi.org/10.1038/s41590-020-0744-z (2020).

  4. Crotty, S. Immunity 50, 1132–1148 (2019).

    Article  CAS  Google Scholar 

  5. Ziegler, A. G. et al. JAMA 309, 2473–2479 (2013).

    Article  CAS  Google Scholar 

  6. Kenefeck, R. et al. J. Clin. Invest. 125, 292–303 (2015).

    Article  Google Scholar 

  7. Viisanen, T. et al. Diabetes 66, 437–447 (2017).

    Article  CAS  Google Scholar 

  8. Ferreira, R. C. et al. Diabetologia 58, 781–790 (2015).

    Article  CAS  Google Scholar 

  9. Verstappen, G. M. et al. Arthritis Rheumatol. 69, 1850–1861 (2017).

    Article  CAS  Google Scholar 

  10. Fukuyo, S. et al. Clin. Exp. Rheumatol. 35, 562–570 (2017).

    PubMed  Google Scholar 

  11. Wang, C. J. et al. Proc. Natl Acad. Sci. USA 112, 524–529 (2015).

    Article  CAS  Google Scholar 

  12. Glatigny, S. et al. J. Immunol. 202, 1373–1382 (2019).

    Article  CAS  Google Scholar 

  13. Linsley, P. S., Greenbaum, C. J., Speake, C., Long, S. A. & Dufort, M. J. JCI Insight 4, e126136 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Estelle Bettelli or Daniel J. Campbell.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bettelli, E., Campbell, D.J. Circulating TFH cells as a marker for early therapeutic intervention in T1D. Nat Immunol 21, 1141–1142 (2020). https://doi.org/10.1038/s41590-020-0766-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-020-0766-6

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing